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Purpose 
The aim of this work is to study the interest of the PGSS (Particles from Gas Saturated Solutions) process for the production of 
fenofibrate lipid based Solid Dispersion (SD). By means of a design of experiments, a Gelucire® 50/13 formulation of fenofibrate and 
the PGSS process were optimized. Then, to evaluate the interest of this PGSS process, several Gelucire® based formulations of 
fenofibrate were assessed both in vitro and in vivo. 
Methods 
The PGSS formulation (fenofibrate + Gelucire® 50/13) and the PGSS process were optimized by means of a design of experiments. 
This optimal PGSS formulation was compared to a classical SD at the same concentration (220 mg of fenofibrate per gram of 
Gelucire®). This classical SD was obtained by melting both products together and micronizing this mixture to obtain a particle size 
comparable to the PGSS product. Initially, these two products were tested in vitro using a biphasic dissolution system. This system 
consisted of a USP II apparatus combined with the USP IV apparatus.  Afterwards, both products were tested in vivo. This study was 
performed on Pietrain crossed Landrace pigs (n = 6) after an overnight fasting period of 12 h. The pharmacokinetic parameters Cmax, 
Tmax and AUC0-t of fenofibric acid were calculated. 
Results 
Regarding the in vitro results (n = 6), the PGSS and the SD formulations had a very similar dissolution profile in the organic phase (f2 
= 61). However, the results were different in the aqueous phase. For the SD formulation, the maximal concentration (Cmax) was 
reached after 10 h and decreased shortly afterwards. The average Cmax was about 155 µg/mL and the calculated Maximum 
Supersaturation Ration (SRM) was 1.89 ± 0.09. In comparison, for the PGSS formulation, Cmax was reached earlier (7 h) and was 
maintained over a longer period (approximately 3 h). This average Cmax was about 190 µg/mL and thus, the calculated SRM was also 
higher (SRM = 2.28 ± 0.14). Given these results, the improvement of the oral bioavailability of fenofibrate should be more pronounced 
with the PGSS formulation as a result both of supersaturation being maintained for a longer period and the higher SRM value attained. 
Regarding the in vivo results (n = 6), the PGSS formulation showed a higher value of Cmax and AUC0-t compared to the SD 
formulation. The Tmax value was also shorter for the PGSS formulation. Therefore, we can conclude that a good correlation of in vitro 
fenofibrate dissolution profiles and in vivo bioavailability can be established. 
Conclusion 
The optimized PGSS formulation and the classical SD were tested in vitro using a biphasic dissolution test and the observations in the 
aqueous phase seem to be well correlated with the results obtained in vivo. Therefore, the PGSS process is interesting compared to a 
classical method such as melt mixing for the production of fenofibrate lipid based SD. This could be probably explained by the high 
porosity of the produced powder and the reduced size of fenofibrate crystals generated by the process. 
